Alzheimer's disease (AD) is a persistent neurological disorder characterized by increasing cognitive impairment and is the most prevalent type of dementia. The most common pathological features are amyloid plaques due to amyloid-β (Aβ) deposits and neurofibrillary tangles (NFTs) consisting of hyperphosphorylated tau proteins that accumulate abnormally in the brain. Nearly a decade of clinical studies and preclinical data have demonstrated that AD shares common pathologic mechanisms with type 2 diabetes mellitus (T2DM), including insulin resistance, oxidative stress, and inflammatory responses. Since they share a common pathological mechanism and AD lacks an effective treatment, it is of great clinical significance to investigate whether AD can be treated with existing T2DM drugs.

Jingfen Wang, Louyan Ma, Yali Lv. New advances in the treatment of Alzheimer's disease with antidiabetic drugs. International Journal of Frontiers in Medicine (2023), Vol. 5, Issue 10: 75-80. https://doi.org/10.25236/IJFM.2023.051012.

[1] Chornenkyy Y, Wang W X, Wei A, et al. Alzheimer's disease and type 2 diabetes mellitus are distinct diseases with potential overlapping metabolic dysfunction upstream of observed cognitive decline [J]. Brain pathology (Zurich, Switzerland), 2019, 29(1): 3-17.

[2] Tumminia A, Vinciguerra F, Parisi M, et al. Type 2 Diabetes Mellitus and Alzheimer's Disease: Role of Insulin Signalling and Therapeutic Implications [J]. International journal of molecular sciences, 2018, 19(11).

[3] Verdile G, Fuller S J, Martins R N. The role of type 2 diabetes in neurodegeneration [J]. Neurobiology of disease, 2015, 84: 22-38.

[4] Cao J, Hou J, Ping J, et al. Advances in developing novel therapeutic strategies for Alzheimer's disease [J]. Molecular neurodegeneration, 2018, 13(1): 64.

[5] De La Monte S M, Tong M. Brain metabolic dysfunction at the core of Alzheimer's disease [J]. Biochemical pharmacology, 2014, 88(4): 548-559.

[6] Kandimalla R, Thirumala V, Reddy P H. Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal [J]. Biochimica et biophysica acta Molecular basis of disease, 2017, 1863(5): 1078-1089.

[7] Akter K, Lanza E A, Martin S A, et al. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? [J]. British journal of clinical pharmacology, 2011, 71(3): 365-376.

[8] Baglietto-Vargas D, Shi J, Yaeger D M, et al. Diabetes and Alzheimer's disease crosstalk [J]. Neuroscience and biobehavioral reviews, 2016, 64: 272-287.

[9] García-Ayllón M S, Riba-Llena I, Serra-Basante C, et al. Altered levels of acetylcholinesterase in Alzheimer plasma [J]. PloS one, 2010, 5(1): e8701.

[10] Markowicz-Piasecka M, Sikora J, Mateusiak Ł, et al. Metformin and Its Sulfenamide Prodrugs Inhibit Human Cholinesterase Activity [J]. Oxidative medicine and cellular longevity, 2017, 2017: 7303096.

[11] Mushtaq G, Greig N H, Khan J A, et al. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus [J]. CNS & neurological disorders drug targets, 2014, 13(8): 1432-1439.

[12] Rao A A, Sridhar G R, Das U N. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease [J]. Medical hypotheses, 2007, 69(6): 1272-1276.

[13] Shingo A S, Kanabayashi T, Kito S, et al. Intracerebroventricular administration of an insulin analogue recovers STZ-induced cognitive decline in rats [J]. Behavioural brain research, 2013, 241: 105-111.

[14] Chen F, Dong R R, Zhong K L, et al. Antidiabetic drugs restore abnormal transport of amyloid-β across the blood-brain barrier and memory impairment in db/db mice [J]. Neuropharmacology, 2016, 101: 123-136.

[15] Craft S, Asthana S, Newcomer J W, et al. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose [J]. Archives of general psychiatry, 1999, 56(12): 1135-1140.

[16] Lioutas V A, Alfaro-Martinez F, Bedoya F, et al. Intranasal Insulin and Insulin-Like Growth Factor 1 as Neuroprotectants in Acute Ischemic Stroke [J]. Translational stroke research, 2015, 6(4): 264-275.

[17] Lv H, Tang L, Guo C, et al. Intranasal insulin administration may be highly effective in improving cognitive function in mice with cognitive dysfunction by reversing brain insulin resistance [J]. Cognitive neurodynamics, 2020, 14(3): 323-338.

[18] Hallschmid M. Intranasal Insulin for Alzheimer's Disease [J]. CNS drugs, 2021, 35(1): 21-37.

[19] Kellar D, Register T, Lockhart S N, et al. Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer's disease: a randomized trial [J]. Scientific reports, 2022, 12(1): 1346.

[20] Barini E, Antico O, Zhao Y, et al. Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy [J]. Molecular neurodegeneration, 2016, 11: 16.

[21] Markowicz-Piasecka M, Sikora J, Szydłowska A, et al. Metformin - a Future Therapy for Neurodegenerative Diseases : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla [J]. Pharmaceutical research, 2017, 34(12): 2614-2627.

[22] Zheng J, Xu M, Walker V, et al. Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer's disease risk in the general population: a Mendelian randomisation study [J]. Diabetologia, 2022, 65(10): 1664-1675.

[23] Ning P, Luo A, Mu X, et al. Exploring the dual character of metformin in Alzheimer's disease [J]. Neuropharmacology, 2022, 207: 108966.

[24] Heneka M T, Rodríguez J J, Verkhratsky A. Neuroglia in neurodegeneration [J]. Brain research reviews, 2010, 63(1-2): 189-211.

[25] Prakash A, Kumar A, Ming L C, et al. Modulation of the Nitrergic Pathway via Activation of PPAR-γ Contributes to the Neuroprotective Effect of Pioglitazone Against Streptozotocin-Induced Memory Dysfunction [J]. Journal of molecular neuroscience : MN, 2015, 56(3): 739-750.

[26] Kunze L H, Ruch F, Biechele G, et al. Long-Term Pioglitazone Treatment Has No Significant Impact on Microglial Activation and Tau Pathology in P301S Mice [J]. International journal of molecular sciences, 2023, 24(12).

[27] Hu S H, Jiang T, Yang S S, et al. Pioglitazone ameliorates intracerebral insulin resistance and tau-protein hyperphosphorylation in rats with type 2 diabetes [J]. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2013, 121(4): 220-224.

[28] Galimberti D, Scarpini E. Pioglitazone for the treatment of Alzheimer's disease [J]. Expert opinion on investigational drugs, 2017, 26(1): 97-101.

[29] Burns D K, Alexander R C, Welsh-Bohmer K A, et al. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial [J]. The Lancet Neurology, 2021, 20(7): 537-547.

[30] Zheng J, Xie Y, Ren L, et al. GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer's disease [J]. Molecular metabolism, 2021, 47: 101180.

[31] Yu C J, Ma D, Song L L, et al. The role of GLP-1/GIP receptor agonists in Alzheimer's disease [J]. Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2020, 29(6): 661-668.

[32] Park J S, Kam T I, Lee S, et al. Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's disease [J]. Acta neuropathologica communications, 2021, 9(1): 78.

[33] Gejl M, Gjedde A, Egefjord L, et al. In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial [J]. Frontiers in aging neuroscience, 2016, 8: 108.

[34] Gejl M, Brock B, Egefjord L, et al. Blood-Brain Glucose Transfer in Alzheimer's disease: Effect of GLP-1 Analog Treatment [J]. Scientific reports, 2017, 7(1): 17490.

[35] Nørgaard C H, Friedrich S, Hansen C T, et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers [J]. Alzheimer's & dementia (New York, N Y), 2022, 8(1): e12268.

[36] Siddiqui N, Ali J, Parvez S, et al. Linagliptin, a DPP-4 inhibitor, ameliorates Aβ (1-42) peptides induced neurodegeneration and brain insulin resistance (BIR) via insulin receptor substrate-1 (IRS-1) in rat model of Alzheimer's disease [J]. Neuropharmacology, 2021, 195: 108662.

[37] Siddiqui N, Ali J, Parvez S, et al. Neuroprotective Role of DPP-4 Inhibitor Linagliptin Against Neurodegeneration, Neuronal Insulin Resistance and Neuroinflammation Induced by Intracerebroventricular Streptozotocin in Rat Model of Alzheimer's Disease [J]. Neurochemical research, 2023, 48(9): 2714-2730.

[38] Mozafari N, Dehshahri A, Ashrafi H, et al. Vesicles of yeast cell wall-sitagliptin to alleviate neuroinflammation in Alzheimer's disease [J]. Nanomedicine : nanotechnology, biology, and medicine, 2022, 44: 102575.

[39] Zhou J B, Tang X, Han M, et al. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis [J]. Metabolism: clinical and experimental, 2020, 109: 154265.

[40] Wu C Y, Ouk M, Wong Y Y, et al. Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status [J]. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2020, 16(12): 1663-1673.

[41] Hierro-Bujalance C, Infante-Garcia C, Del Marco A, et al. Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes [J]. Alzheimer's research & therapy, 2020, 12(1): 40.

[42] Pang B, Zhang L L, Li B, et al. The sodium glucose co-transporter 2 inhibitor ertugliflozin for Alzheimer's disease: Inhibition of brain insulin signaling disruption-induced tau hyperphosphorylation [J]. Physiology & behavior, 2023, 263: 114134.

[43] Rizvi S M, Shakil S, Biswas D, et al. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study [J]. CNS & neurological disorders drug targets, 2014, 13(3): 447-451.

[44] Wu C Y, Iskander C, Wang C, et al. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study [J]. Diabetes care, 2023, 46(2): 297-304.

[45] Avgerinos K I, Mullins R J, Vreones M, et al. Empagliflozin Induced Ketosis, Upregulated IGF-1/Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics [J]. Cells, 2022, 11(21).